Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Review Article

Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies

Author(s): Senthamil R. Selvan, John P. Dowling, William K. Kelly and Jianqing Lin

Volume 16, Issue 9, 2016

Page: [755 - 764] Pages: 10

DOI: 10.2174/1568009615666151030102250

Price: $65

conference banner
Abstract

Indoleamine 2,3-dioxygenase (IDO) is a heme-containing oxidoreductase that catalyzes the initial and rate-limiting step in the breakdown of non-dietary tryptophan. The biology and immunomodulatory role for IDO is discussed in this review with a focus on its interaction with immune cells and its potential therapeutic target in the clinic. IDO has been revealed to be a central regulator of immune responses in a broad variety of physiological and pathological settings, mostly serving as a multifaceted negative feedback mechanism, to self-regulate immune responses. IDO is considered a therapeutic target in cancer and the use of IDO inhibitors as single agent or in combination with other treatment modalities are under active investigation.

Keywords: Cancer immunotherapy, combination therapy, indoleamine 2, 3-dioxygenase (IDO), IDO inhibitors, immune tolerance.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy